As of today (2023-05-29), Intercept Pharmaceuticals's share price is $10.26.
Intercept Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.36. Hence, Intercept Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is .
The historical rank and industry rank for Intercept Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Intercept Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 207.13. The lowest was 0.00. And the median was 188.74.
ICPT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.93 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 52.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 41.90% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 5.70% per year.
During the past 13 years, Intercept Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 52.40% per year. The lowest was -104.70% per year. And the median was 18.90% per year.
Intercept Pharmaceuticals Price-to-Free-Cash-Flow Historical Data
The historical data trend for Intercept Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Intercept Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Price-to-Free-Cash-Flow
-
-
-
-
-
Intercept Pharmaceuticals Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Price-to-Free-Cash-Flow
-
158.74
-
-
-
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals Price-to-Free-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's Price-to-Free-Cash-Flow falls in comparison to its industry or sector. The grey bar indicates the Price-to-Free-Cash-Flow's extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals's Share Price of today is $10.26.
Intercept Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Intercept Pharmaceuticals Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (NAS:ICPT) Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.51(5.23%) Volume: 1,489,063 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 
